# CBD for Anxiety: Insights from Neuroimaging Studies > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-neuroimaging-anxiety-review/ > **Published:** 2026-07-24T08:35:47-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:54:57-04:00 > **Clinical Summary:** Explore the cbd neuroimaging anxiety review revealing inconsistent brain-imaging findings and very low certainty evidence on CBD's effects for anxiety and stress. --- CED Clinical Relevance #80 Rigorous Review, Inconsistent Signal A July 9, 2026 PROSPERO-registered [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) pooled every adult human neuroimaging study comparing CBD with placebo in stress or anxiety paradigms. Across 12 studies and 146 participants, the certainty of evidence for CBD’s neural effects was graded Very Low, and self-reported anxiety rarely differed from placebo. Clinical Insight | CED Clinic A [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) published July 9, 2026 in Frontiers in Neuroimaging asked a narrow, useful question: when researchers put people in a scanner, give them CBD or placebo, and expose them to a stress or anxiety task, does a consistent brain signature for CBD’s anxiolytic effect show up. The review, registered in advance with PROSPERO, searched PubMed, Web of Science, EBSCO, and ProQuest through June 30, 2025, and identified 1,470 records that narrowed to 12 eligible studies spanning 146 participants across seven cohorts. Using the Cochrane Risk of Bias 2 tool and the GRADE framework, the authors found reported brain-activity peaks scattered across many cortical and subcortical regions, in both directions, with no single region or brain network showing a consistent CBD effect. Self-reported anxiety also rarely differed between CBD and placebo. This is exactly the kind of unglamorous, rigorous accounting that clinicians need before repeating the popular claim that CBD calms an overactive amygdala. CBDAnxietySystematic ReviewNeuroimagingEvidence Quality Audience Primary care and cannabis-medicine clinicians, psychiatrists, and patients considering CBD for stress or anxiety symptoms. Primary Topic A July 9, 2026 systematic review of 12 human neuroimaging studies testing whether CBD produces a consistent brain-based anxiolytic signature relative to placebo. Source [Read the full source](https://www.frontiersin.org/journals/neuroimaging/articles/10.3389/fnimg.2026.1860919/full) ## CBD for Anxiety: What 12 Brain-Imaging Studies Actually Show A new PROSPERO-registered systematic review pooled every adult human neuroimaging study comparing CBD with placebo in stress and anxiety paradigms. Across 12 studies and 146 participants, brain-activity findings pointed in inconsistent directions, self-reported anxiety rarely improved more than placebo, and the certainty of evidence was rated Very Low. Here is what the review actually found, and what it does not settle. What This Study Teaches Us This review teaches that a plausible neurobiological story, in this case CBD calming stress- and fear-related brain circuits, is not the same thing as a replicated neuroimaging finding. Twelve studies using different doses, tasks, and scanning methods produced scattered, often contradictory results rather than a convergent brain signature. Why This Matters Patients frequently ask about [CBD for anxiety](https://cedclinic.com/cannabidiol-oil-pediatric-anxiety-insomnia-case-report/) based on marketing claims that it works by quieting the amygdala or calming a hyperactive stress response. This review is the first systematic attempt to pool the actual human neuroimaging evidence behind that claim, and it found substantial heterogeneity rather than convergence. That distinction matters directly for how clinicians frame expectations when patients ask whether CBD will measurably change how their brain responds to stress. Study Snapshot Study Type Systematic review of adult human neuroimaging studies, PROSPERO registered Registration PROSPERO CRD420251063369 Databases Searched PubMed, Web of Science, EBSCO, ProQuest, through June 30, 2025 Included Studies 12 studies, 146 participants, 7 cohorts (published 2004 to 2025) Screening 1,470 records identified; 68 full texts assessed; 12 met eligibility CBD Doses Used Single doses from 125 mg to 800 mg across included studies Risk of Bias Tool Cochrane Risk of Bias 2 (RoB 2) Certainty Framework GRADE: neuroimaging Very Low, behavioral Very Low, physiological Low Journal Frontiers in Neuroimaging Published July 9, 2026 DOI 10.3389/fnimg.2026.1860919 Authors Rutledge O, Goyette RB, Wang KL, Park MS, Gabrieli JDE (MIT) Clinical Use Evidence-grading reference for [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/), not standalone treatment proof Clinical Bottom Line This review does not identify a consistent brain-imaging signature for CBD’s anxiolytic effect, and most included studies found no significant difference between CBD and placebo on self-reported anxiety, though the evidence base remains small, heterogeneous, and rated very low certainty rather than definitively negative. What This Review Actually Evaluated The review was not a single new brain-imaging trial of CBD. It was a preregistered synthesis of every eligible adult human study that scanned participants with fMRI, PET, or SPECT while comparing CBD against placebo in a stress or anxiety context, from the earliest eligible study in 2004 through mid-2025. That design matters for how the findings should be read. The authors were not testing a single dose or paradigm. They were asking whether, across 12 independently designed studies, a consistent neural pattern for CBD emerged at all. Why the Scattered Findings Deserve Attention Across six task-based fMRI studies reporting whole-brain results, 44 peak coordinates were pooled into an anatomic vote count. The result was 12 votes for increased activation and 12 votes for decreased activation, with reported effects most frequently located in the occipital lobe, itself split between both directions. A network-level analysis using the Yeo seven-network parcellation found a similar pattern: 8 votes for increased activation and 12 for decreased activation, with the ventral attention or salience network the only network showing a uniform direction, all three votes reflecting decreased activation. No single network was implicated consistently across all studies. The Amygdala Findings Specifically The amygdala is the brain region most often invoked in popular claims about CBD and anxiety, so the review’s amygdala-specific findings are worth isolating. One included study (Bird, 2022) found decreased left amygdala activation with CBD relative to placebo. A separate study using dynamic causal modeling (Fusar-Poli et al., 2010) found that CBD disrupted forward connectivity from the anterior cingulate cortex to the amygdala during a fearful-faces task. These are real, individually reported findings, not fabricated ones, and they are consistent with a biologically plausible story. But they come from a small number of studies within a 12-study pool that, taken as a whole, did not converge on a single consistent regional or network-level pattern. What Happened to Self-Reported Anxiety Brain-imaging changes and how anxious someone actually reports feeling are two different outcomes, and the review kept them separate. Across most of the included studies, no significant difference was found between CBD and placebo on subjective measures of anxiety or stress. Two studies did report a modest reduction in self-reported anxiety with CBD relative to placebo, and one study (Zimmermann et al., 2025) found significantly reduced alcohol craving following cue exposure in participants who received CBD. These exceptions do not overturn the overall pattern, but they are part of the record and are reported here rather than omitted. Why the Evidence Was Graded So Low The GRADE framework rated certainty of evidence for neuroimaging measures and behavioral measures as Very Low, and for physiological measures as Low. Risk-of-bias assessments using RoB 2 generally showed either some concerns or high risk of bias across the included studies. The authors also flagged that several reports drew on overlapping or partially overlapping participant cohorts, meaning the apparent number of independent findings overstates the actual independent evidence base. Combined with small sample sizes and study populations that were predominantly white and male, this substantially limits how far the findings can be generalized. How Strong Is This Evidence? This is a preregistered, PROSPERO-listed systematic review that applied the Cochrane RoB 2 tool and the GRADE framework, searched four databases plus grey literature, and screened 1,470 records down to 12 eligible studies with documented inter-rater agreement. That is a rigorous review structure, and the review’s conclusion that the evidence is inconsistent and low certainty is itself a well-supported, methodologically earned finding. Where This Paper Deserves Skepticism The underlying evidence base is thin: 12 studies, 146 participants, and only seven independent cohorts, with some studies sharing overlapping participants. A planned voxel-based meta-analysis (SDM-PSI) could not be performed because too few studies reported comparable statistical information, so the review relied on a narrative vote-counting synthesis rather than a pooled quantitative estimate. Doses, tasks, imaging modalities, and timing varied widely across studies, which limits how directly any single finding, including the amygdala results, can be compared to another. What This Paper Does Not Show This review does not show that CBD has no biological effect on stress- or fear-related brain circuitry. Several individual studies, including the amygdala and amygdala-ACC connectivity findings, reported real effects. What the review does not show is a single, consistent, replicated neuroimaging signature for CBD across the available human studies, and it does not show that CBD reliably reduces self-reported anxiety more than placebo across this literature. It also does not evaluate CBD for diagnosed [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) specifically, since most included studies used healthy volunteers or experimentally induced stress or fear paradigms rather than clinical anxiety populations. How This Fits With the Broader Clinical Conversation CED Clinic has previously covered a related brain-imaging finding in a different population: an acute oral THC study in adults with PTSD found that 5 mg and 10 mg doses reduced prefrontal activation during emotion regulation, yet produced no corresponding improvement in self-reported negative affect. That study and this CBD review point to the same underlying caution, that a measurable brain-imaging change does not automatically translate into a measurable symptom change. CED has also covered a broader Lancet Psychiatry systematic review of RCT evidence for cannabinoids across psychiatric and neurological conditions, which identified significant gaps in standardized outcome measurement. This CBD neuroimaging review adds a specific, mechanism-level example of exactly that outcome-measurement gap. Dr. Caplan’s Take *I regularly hear patients describe CBD as something that will calm an overactive amygdala, usually repeating language from a product website rather than a study. This review is a useful corrective. Individual studies do report amygdala and amygdala-connectivity changes with CBD, so that language is not invented out of nothing, but the review makes clear those findings sit inside a small, heterogeneous, very-low-certainty evidence base rather than a settled neuroscience finding.* *What I take from this into the exam room is not that CBD does nothing for stress or anxiety. Some patients report real subjective benefit, and a few of the included studies found modest reductions in self-reported anxiety. What I will stop doing is describing CBD’s mechanism in confident neuroanatomical terms it has not yet earned. The honest answer right now is that we do not have a consistent brain-imaging explanation for why some patients feel calmer on CBD.* What a Careful Reader Should Take Away A careful reader should take away that this review strengthens the case for precise, mechanism-honest counseling about CBD and anxiety: individual brain-imaging findings exist and are not fabricated, but they have not yet converged into a reliable, replicated signature, and self-reported anxiety benefit was inconsistent across the pooled studies. Evidence Interpretation Guide ## How to Read a Neuroimaging Systematic Review Without Overclaiming or Dismissing It Pooled neuroimaging reviews are easy to misread in either direction, either by citing one striking individual finding as if it were the field’s consensus, or by treating a Very Low certainty rating as proof that nothing is happening biologically. The right approach is to separate what individual studies reported from what the pooled evidence, taken as a whole, actually supports. ### Four questions worth asking before you trust a neuroimaging synthesis **How many independent cohorts actually contributed data?**This review’s 12 studies came from only seven independent cohorts, with some cohorts contributing more than one report. That is a smaller independent evidence base than the raw study count suggests. **Did the findings converge, or scatter?**The whole-brain, network-level, and SPECT perfusion analyses each showed activation changes in roughly equal numbers of increases and decreases, with no single brain region or network implicated consistently across studies. **Did brain changes track with how people actually felt?**Most included studies found no significant difference between CBD and placebo on self-reported anxiety, even when some individual brain-imaging changes were detected. Two studies were exceptions, reporting modest self-reported anxiety reductions. **What certainty grade did the authors themselves assign?**The GRADE framework rated neuroimaging and behavioral evidence Very Low and physiological evidence Low, which reflects both a small, heterogeneous evidence base and meaningful risk of bias across the RoB 2 assessments. The Research Question Across adult human neuroimaging studies comparing CBD with placebo in stress or anxiety paradigms, is there a consistent, replicated pattern of CBD-related brain activity change, and does it correspond to reduced self-reported anxiety? The Patient Question If I take [CBD for anxiety](https://cedclinic.com/cannabidiol-oil-pediatric-anxiety-insomnia-case-report/), does this review mean it is not doing anything in my brain, and should I stop? The Bottom Line The review’s best-supported conclusion is that current human neuroimaging evidence for CBD’s anxiolytic mechanism is inconsistent and very low certainty, not that CBD has no effect. Individual [patient response](https://cedclinic.com/mental-health-research-quality-cannabis-study/), dosing, and any decision about continuing or adjusting CBD use should be discussed with your treating clinician rather than decided from this review alone. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview This review changes the conversation most when readers separate individually reported brain-imaging findings, some of which are genuinely interesting, from the pooled evidence as a whole, which has not yet converged into a consistent, replicated mechanism for CBD’s effects on stress and anxiety. #### What This Means If You Take (or Are Considering) CBD for Anxiety If you were told CBD works by calming an overactive amygdala, this review shows that claim is based on a small number of individual studies rather than a consistent, replicated brain-imaging finding across the field. That does not mean CBD is doing nothing for you if you feel calmer after taking it. Subjective response and neuroimaging convergence are different kinds of evidence, and this review specifically found that most studies did not show a self-reported anxiety benefit over placebo, though two did. The most useful next step is discussing your specific goals, dose, and response pattern with your clinician rather than relying on mechanism claims from marketing material. Lens takeaway Use this review to set realistic expectations about what is and is not scientifically established about how CBD affects the anxious brain. #### What a Responsible Clinician Can Say About This Finding A responsible clinician can now say, with real evidentiary backing, that the human neuroimaging literature on CBD and anxiety is small, heterogeneous, and has not produced a consistent regional or network-level signature, despite individual studies reporting amygdala-related changes. A responsible clinician should also avoid overstating the negative side of this finding. Two studies found modest self-reported anxiety improvement, and the review’s Very Low certainty rating reflects evidence quality and heterogeneity, not a conclusion that CBD is ineffective. Lens takeaway This review supports precise, mechanism-honest counseling rather than either confident neurobiological claims or blanket dismissal. #### Why a Cautious Reader Should Slow Down Only seven independent cohorts underlie the 12 included studies, and a planned quantitative meta-analysis could not be performed because too few studies reported comparable statistical detail. That is a narrow evidence base for a topic this widely discussed in consumer marketing. A skeptical reader should also note that doses ranged from 125 mg to 800 mg across studies using different tasks and scanning modalities, which makes it difficult to know whether inconsistent findings reflect a truly inconsistent biological effect or simply methodological variation across small studies. Lens takeaway The evidence base is real but thin, and its inconsistency may reflect study design variability as much as biology. #### Where the Methodologic Pressure Points Are The biggest pressure point is non-independence of findings. The authors explicitly note that overlapping peak coordinates across studies were often attributable to the same cohort, meaning the apparent volume of evidence overstates the number of truly independent replications. A second pressure point is the demographic composition of the pooled sample. The authors state that participants were predominantly white males, which limits how confidently these findings, whatever direction they point, can be generalized to more diverse patient populations. Lens takeaway Non-independent samples and a narrow demographic base are the two clearest limitations to weigh before generalizing this review’s findings. #### How This Fits With Earlier CED Coverage on Brain Imaging and Cannabinoids CED Clinic previously covered an acute oral THC study in adults with PTSD that found reduced prefrontal activation during emotion regulation at 5 mg and 10 mg doses, without a corresponding improvement in self-reported negative affect. This CBD review reaches a structurally similar conclusion from a different angle: brain-imaging change and symptom change do not automatically move together. CED has also covered a broader Lancet Psychiatry review documenting outcome-measurement gaps in cannabinoid psychiatric research generally. This review’s finding, that self-reported anxiety often did not track brain-imaging changes, is a concrete illustration of that broader measurement problem. Lens takeaway This review reinforces a pattern CED has already reported elsewhere: cannabinoid brain-imaging changes and patient-reported symptom relief frequently diverge. #### What Changes in the Exam Room What changes is the specificity of the mechanism conversation. Clinicians can now cite a preregistered systematic review when explaining that CBD’s brain-imaging effects on stress and anxiety circuitry have not been consistently replicated across the available human studies. What does not change is the value of tracking a given patient’s actual reported response. Since neuroimaging convergence was absent but a minority of studies did find self-reported anxiety benefit, individual response monitoring remains the most clinically useful signal available today. Lens takeaway The practical gain is a more honest mechanism conversation, paired with continued reliance on individual patient-reported response rather than brain-imaging claims. #### What Better Evidence Needs Next The authors call for standardized experimental paradigms, improved reporting practices, and more diverse, adequately powered samples to clarify the neural correlates of CBD’s effects on stress and anxiety. Given that overlapping cohorts inflated the apparent evidence base in this review, independent replication in new, demographically diverse cohorts using consistent dosing and imaging protocols would meaningfully strengthen the next synthesis. Lens takeaway Standardized, adequately powered, demographically diverse replication studies are the clearest next step this review points toward. #### How This Review Could Be Distorted, and What It Actually Says Distortion 1: “This proves CBD does nothing for anxiety.” False. Individual studies reported real brain-imaging changes, including amygdala-related findings, and two studies found modest self-reported anxiety benefit. Distortion 2: “Brain scans confirm CBD calms the amygdala.” False. Only a small number of the 12 included studies reported amygdala-specific findings, and the pooled evidence across all regions and networks did not converge on a consistent pattern. Distortion 3: “Very Low certainty means the study was poorly done.” False. The Very Low GRADE rating reflects the size, heterogeneity, and risk of bias in the underlying literature, not a flaw in this review’s own rigorous, preregistered methodology. Lens takeaway The accurate reading is specific and narrow: some individual neuroimaging findings exist, but no consistent, replicated pattern has emerged, and certainty of evidence is low. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CBD+for+Anxiety%3A+What+12+Brain-Imaging+Studies+Actually+Show&url=https%3A%2F%2Fcedclinic.com%2Fcbd-neuroimaging-anxiety-stress-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-neuroimaging-anxiety-stress-review%2F) [BlueSky](https://bsky.app/intent/compose?text=CBD+for+Anxiety%3A+What+12+Brain-Imaging+Studies+Actually+Show%20https%3A%2F%2Fcedclinic.com%2Fcbd-neuroimaging-anxiety-stress-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review.](https://www.frontiersin.org/journals/neuroimaging/articles/10.3389/fnimg.2026.1860919/full) Related Reading at CED Clinic Continue exploring the evidence [THC and PTSD Emotion Regulation: What a New Brain-Imaging Study Actually Found](https://cedclinic.com/acute-oral-thc-cognitive-reappraisal-ptsd-study/) A related CED report on a cannabinoid brain-imaging study where measurable prefrontal changes did not translate into self-reported symptom improvement, the same dissociation seen in this CBD review. [Read the PTSD imaging study](https://cedclinic.com/acute-oral-thc-cognitive-reappraisal-ptsd-study/) [Medical Cannabis for Anxiety & Tourette: Clinical Evidence](https://cedclinic.com/cannabinoid-clinical-trials-anxiety-review/) Earlier CED coverage of clinical trial evidence for cannabinoids in anxiety and Tourette syndrome, useful clinical-outcome context alongside this neuroimaging-focused review. [Review the clinical trial evidence](https://cedclinic.com/cannabinoid-clinical-trials-anxiety-review/) [Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine](https://cedclinic.com/measuring-what-matters-why-outcomes-will-decide-the-future-of-cannabis-medicine/) A broader CED look at outcome-measurement gaps across cannabinoid psychiatric and neurological research, the same gap this review illustrates for CBD and anxiety specifically. [See the broader evidence picture](https://cedclinic.com/measuring-what-matters-why-outcomes-will-decide-the-future-of-cannabis-medicine/) ## Frequently Asked Questions What did this new systematic review actually study? It pooled every eligible adult human neuroimaging study, using fMRI, PET, or SPECT, that compared CBD with placebo in a stress or anxiety context, identifying 12 studies with 146 participants across seven cohorts published between 2004 and 2025. Did the review find that CBD calms the amygdala? A small number of the included studies reported amygdala-related findings, including decreased left amygdala activation in one study and disrupted amygdala-connectivity in another. But across all 12 studies and every brain region examined, no single consistent pattern emerged. Did CBD reduce self-reported anxiety in these studies? In most of the included studies, there was no significant difference between CBD and placebo on self-reported anxiety or stress. Two studies did find a modest reduction in self-reported anxiety with CBD, and one study found reduced alcohol craving after cue exposure. What does a ‘Very Low certainty’ GRADE rating mean here? It means the authors judged the neuroimaging and behavioral evidence to be of very low certainty due to small sample sizes, methodological heterogeneity, overlapping study cohorts, and risk of bias, not that CBD was proven ineffective. How many studies and participants were included overall? Twelve studies met eligibility criteria, comprising 146 participants across seven separate cohorts. Some cohorts contributed to more than one included study. What CBD doses were used in the reviewed studies? Single CBD doses across the included studies ranged from 125 mg to 800 mg. The review’s eligibility criteria accepted studies using doses from 100 mg to 1,000 mg. Was this review preregistered? Yes. It was registered in advance with PROSPERO under registration number CRD420251063369, and risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Why couldn’t the authors run a full statistical meta-analysis? A planned voxel-based meta-analysis using Seed-based d Mapping was attempted but could not be completed because too few studies reported comparable statistical information, so the authors used a narrative Synthesis Without Meta-analysis (SWiM) approach instead. Does this mean patients should stop using CBD for anxiety? Not necessarily, and that would be overreading the review. It addresses whether a consistent brain-imaging signature exists, not whether individual patients can experience subjective benefit. Any change in CBD use should be discussed with a treating clinician. What should clinicians and patients take away from this review right now? The most defensible takeaway is that current human neuroimaging evidence does not show a consistent, replicated brain-based mechanism for CBD’s anxiolytic effects, while individual studies and patient-reported responses remain areas worth tracking on a case-by-case basis with a treating clinician.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).